Description
BSE admits Secured Redeemable Non-Convertible Debentures of ICL Fincorp Limited to dealings on the Exchange effective April 29, 2026, under the F Group segment.
Summary
BSE has admitted Secured Redeemable Non-Convertible Debentures (NCDs) of ICL Fincorp Limited to dealings on the Exchange effective Wednesday, April 29, 2026. The securities are listed under the ‘F Group’ and will be traded exclusively in dematerialized form with a unit market lot of one bond.
Key Points
- Secured Redeemable Non-Convertible Debentures of ICL Fincorp Limited admitted to BSE with effect from April 29, 2026
- Securities listed under the ‘F GROUP’ on the Debt segment
- Trading permitted only in dematerialized form, per SEBI guidelines dated February 16, 2000
- Market lot size: One Bond (unit market lot)
- ICL Fincorp Limited’s financial year ends on March 31
- Registrar and Share Transfer Agent: Cameo Corporate Services Limited, Chennai
Regulatory Changes
No new regulatory changes introduced. Trading is governed by existing SEBI guidelines dated February 16, 2000, mandating dematerialized form for bond trading.
Compliance Requirements
- Trading Members must ensure all trades in this scrip are executed in dematerialized form only
- Trades must be in unit market lot (one bond per lot)
- Trading Members requiring clarification may contact ICL Fincorp Limited’s Compliance Officer (Visakh T.V, cs@iclfincorp.com) or BSE’s Mr. Hardik Bhuta (022-22728814)
Important Dates
- April 28, 2026: Notice date
- April 29, 2026: Effective date for commencement of dealings on BSE
Impact Assessment
This is a routine debt listing notice with limited market impact. It expands the tradeable debt instruments on BSE’s debt segment by adding ICL Fincorp Limited’s NCDs. The listing provides investors with an exchange-based liquidity avenue for these debentures. Impact is confined to trading members and investors specifically interested in ICL Fincorp’s debt securities.
Impact Justification
Routine debt listing notice for NCDs of a single company; no regulatory changes, no broad market impact, affects only trading members dealing in this specific scrip.